ArticleHereditas2025
Therapeutic effects of Bushen Chushi formula on knee osteoarthritis via modulation of MAPK/SLC7A11/GPX4 signaling in rats.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis at the intersection of osteoarthritis and bone metabolism: mechanistic links and therapeutic prospects.Frontiers in cell and developmental biology · 2025Review
- Glutathione peroxidase 4 as an emerging therapeutic target in osteoarthritis: focus on ferroptosis.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe aim of this study is to evaluate the therapeutic efficacy of Bushen Chushi Formula (BSCSF) in a rat model of knee osteoarthritis (KOA), with a focus on the modulation of ferroptosis-related signaling pathways and inflammatory responses, and to assess its effects on cartilage integrity and subchondral bone microstructure.
methodsA total of 66 male Sprague-Dawley rats were randomly assigned to six groups: control, model, diclofenac sodium (DCF), and BSCSF high-dose (BSCSF-H), medium-dose (BSCSF-M), and low-dose (BSCSF-L) groups. KOA was induced via intra-articular injection of monosodium iodoacetate. Following induction, BSCSF or DCF was administered orally for 4 weeks. Therapeutic outcomes were assessed through Lequesne MG scores, body weight measurements, histopathological evaluation (hematoxylin and eosin, Safranin O-Fast Green staining), and micro-computed tomography of the subchondral bone. Expression levels of ferroptosis-associated proteins (SLC7A11, GPX4, p38 MAPK, MMP-13), glutathione (GSH), and iron accumulation (Fe²⁺), as well as inflammatory cytokines (IL-1β, TNF-α), were also measured.
resultsWhen compared to the model group, rats in the BSCSF-H and BSCSF-M groups exhibited significantly lower Lequesne MG scores, improved cartilage morphology, and enhanced subchondral bone microstructure, as indicated by increased bone volume fraction, trabecular thickness, trabecular number, and connectivity density along with decreased bone surface-to-volume ratio and trabecular separation. These groups also demonstrated increased expression of SLC7A11 and GPX4, elevated GSH levels, and reduced Fe²⁺ accumulation in cartilage, suggesting attenuation of ferroptosis. Inflammatory mediators, including IL-1β, TNF-α, MMP-13, and p38 MAPK, were significantly downregulated, indicating reduced inflammation and extracellular matrix degradation. The BSCSF-L group indicated modest improvements, primarily in inflammatory parameters and joint function.
conclusionBSCSF attenuated KOA progression in rats by inhibiting ferroptosis through the MAPK/SLC7A11/GPX4 signaling axis and suppressing inflammatory responses. The observed preservation of cartilage structure and enhancement of subchondral bone quality highlight its therapeutic potential in the management of KOA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.